메뉴 건너뛰기




Volumn 5, Issue 3, 2013, Pages 135-139

Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas

Author keywords

Cisplatin; Irinotecan; Neuroendocrine carcinoma; Neuroendocrine tumors

Indexed keywords

CARBOPLATIN; CISPLATIN; IRINOTECAN; KI 67 ANTIGEN;

EID: 84884616839     PISSN: 20363605     EISSN: 20363613     Source Type: Journal    
DOI: 10.4081/rt.2013.e39     Document Type: Article
Times cited : (19)

References (31)
  • 2
    • 84871555750 scopus 로고    scopus 로고
    • Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
    • Sorbye H, Welin S, Langer SW et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013;24:152-60.
    • (2013) Ann Oncol , vol.24 , pp. 152-160
    • Sorbye, H.1    Welin, S.2    Langer, S.W.3
  • 3
    • 0026747929 scopus 로고
    • Extr a-pulmonary and pulmonary small-cell carcinoma: Tumor biology, therapy, and outcome
    • Remick SC, Ruckdeschel JC. Extr a-pulmonary and pulmonary small-cell carcinoma: tumor biology, therapy, and outcome. Med Pediatr Oncol 1992;20:89-99.
    • (1992) Med Pediatr Oncol , vol.20 , pp. 89-99
    • Remick, S.C.1    Ruckdeschel, J.C.2
  • 4
    • 4344689150 scopus 로고    scopus 로고
    • Small cell carcinomas of the gastrointestinal tract: A review
    • Brenner B, Tang LH, Klimstra DS et al. Small cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol 2004; 22: 2730-9.
    • (2004) J Clin Oncol , vol.22 , pp. 2730-2739
    • Brenner, B.1    Tang, L.H.2    Klimstra, D.S.3
  • 5
    • 46449110634 scopus 로고    scopus 로고
    • One hundred years after carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
    • Yao JC, Eisner MP, Leary C, et al. One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.
    • (2008) J Clin Oncol , vol.26 , pp. 3063-3072
    • Yao, J.C.1    Eisner, M.P.2    Leary, C.3
  • 6
    • 1842339356 scopus 로고    scopus 로고
    • An analysis of 8305 cases of carcinoid tumors
    • Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997; 79:813-29.
    • (1997) Cancer , vol.79 , pp. 813-829
    • Modlin, I.M.1    Sandor, A.2
  • 7
    • 0035447766 scopus 로고    scopus 로고
    • Treatment with cisplatin and etoposide in patients with neuroendocrine tumors
    • Fjallskog ML, Granberg DP, Welin SL, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001;92:1101-7.
    • (2001) Cancer , vol.92 , pp. 1101-1107
    • Fjallskog, M.L.1    Granberg, D.P.2    Welin, S.L.3
  • 8
    • 0025933213 scopus 로고
    • Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin
    • Moertel CG, Kvols LK, O'Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Cancer 1991;68:227-32.
    • (1991) Cancer , vol.68 , pp. 227-232
    • Moertel, C.G.1    Kvols, L.K.2    O'Connell, M.J.3
  • 9
    • 0032734719 scopus 로고    scopus 로고
    • Treatment of poorly differentiated neuroendocrine tumors with etoposide and cisplatin
    • Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumors with etoposide and cisplatin. Br J Cancer 1999;81:1351-5.
    • (1999) Br J Cancer , vol.81 , pp. 1351-1355
    • Mitry, E.1    Baudin, E.2    Ducreux, M.3
  • 10
    • 0033840109 scopus 로고    scopus 로고
    • Chemotherapy in the treatment of neuroendocrine malignant tumors
    • Rougier P, Mitry E. Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 2000;62 (Suppl 1):73-8.
    • (2000) Digestion , vol.62 , Issue.SUPPL. 1 , pp. 73-78
    • Rougier, P.1    Mitry, E.2
  • 11
    • 33747061873 scopus 로고    scopus 로고
    • Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: A Minnie Pearl Cancer Research Network study
    • Hainsworth JD, Thompson DS, Urba WJ, et al. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network study. J Clin Oncol 2006;24:3548-54.
    • (2006) J Clin Oncol , vol.24 , pp. 3548-3554
    • Hainsworth, J.D.1    Thompson, D.S.2    Urba, W.J.3
  • 12
    • 0242349455 scopus 로고    scopus 로고
    • A pilot study of irinotecan plus cisplatin in patients with metastatic high-grade neuroendocrine carcinoma
    • Hou Z, Elasmar A, Lozano R, et al. A pilot study of irinotecan plus cisplatin in patients with metastatic high-grade neuroendocrine carcinoma. Proc Am Soc Clin Oncol 2003;22:375.
    • (2003) Proc Am Soc Clin Oncol , vol.22 , pp. 375
    • Hou, Z.1    Elasmar, A.2    Lozano, R.3
  • 13
    • 66149091639 scopus 로고    scopus 로고
    • A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma
    • Mani M, Shroff RT, Jacobs C, et al. A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma. J Clin Oncol 2008; 26S:15550.
    • (2008) J Clin Oncol , vol.26 S , pp. 15550
    • Mani, M.1    Shroff, R.T.2    Jacobs, C.3
  • 14
    • 33746449124 scopus 로고    scopus 로고
    • A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors
    • Kulke MH, Wu B, Ryan DP, et al. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci 2006; 51:1033.
    • (2006) Dig Dis Sci , vol.51 , pp. 1033
    • Kulke, M.H.1    Wu, B.2    Ryan, D.P.3
  • 15
    • 26844517731 scopus 로고    scopus 로고
    • Endocrine tumours of the gastrointestinal tract. Introduction: Definition, historical aspects, classification, staging, prognosis and therapeutic options
    • Arnold R. Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options. Best Pract Res Clin Gastroenterol 2005;19:491-505.
    • (2005) Best Pract Res Clin Gastroenterol , vol.19 , pp. 491-505
    • Arnold, R.1
  • 16
    • 79851500081 scopus 로고    scopus 로고
    • Everolimus for advanced pancreatic neuroendocrine tumors
    • Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23.
    • (2011) N Engl J Med , vol.364 , pp. 514-523
    • Yao, J.C.1    Shah, M.H.2    Ito, T.3
  • 17
    • 79851482955 scopus 로고    scopus 로고
    • Sunitinib Malate for the treatment of pancreatic neuroendocrine tumors
    • Raymond E, Dahan L, Raoul JL, et al. Sunitinib Malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13.
    • (2011) N Engl J Med , vol.364 , pp. 501-513
    • Raymond, E.1    Dahan, L.2    Raoul, J.L.3
  • 18
    • 83255167036 scopus 로고    scopus 로고
    • Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumors associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study
    • Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumors associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005-12.
    • (2011) Lancet , vol.378 , pp. 2005-2012
    • Pavel, M.E.1    Hainsworth, J.D.2    Baudin, E.3
  • 19
    • 84884606524 scopus 로고    scopus 로고
    • Poorly differentiated neoendocrine tumors
    • In: Yao JC, Hoff PM, Hoff AO, eds. 1st ed. New York: Humana Press
    • Bezerra JE, Riechelamann RP, Hoff PM. Poorly differentiated neoendocrine tumors. In: Yao JC, Hoff PM, Hoff AO, eds. Neuroendocrine tumors. 1st ed. New York: Humana Press; 2011.
    • (2011) Neuroendocrine tumors
    • Bezerra, J.E.1    Riechelamann, R.P.2    Hoff, P.M.3
  • 20
    • 0033797356 scopus 로고    scopus 로고
    • A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis
    • Mascaux C, Paesmans M, Berghmans T, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000;30:23-36.
    • (2000) Lung Cancer , vol.30 , pp. 23-36
    • Mascaux, C.1    Paesmans, M.2    Berghmans, T.3
  • 21
    • 0024420890 scopus 로고
    • Complete remission of refractory small cell carcinoma of the pancreas with cisplatin and etoposide
    • Morant R, Bruckner HW. Complete remission of refractory small cell carcinoma of the pancreas with cisplatin and etoposide. Cancer 1989;64:2007-9.
    • (1989) Cancer , vol.64 , pp. 2007-2009
    • Morant, R.1    Bruckner, H.W.2
  • 22
    • 0023851785 scopus 로고
    • Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin and vincristine in limited small cell lung cancer
    • Einhorn LH, Crawford J, Birch R, et al. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin and vincristine in limited small cell lung cancer. J Clin Oncol 1988;6:451-6.
    • (1988) J Clin Oncol , vol.6 , pp. 451-456
    • Einhorn, L.H.1    Crawford, J.2    Birch, R.3
  • 23
    • 0031887545 scopus 로고    scopus 로고
    • Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer
    • Kudoh S, Fujiwara Y, Takada Y, et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J Clin Oncol 1998; 16:1068-7.
    • (1998) J Clin Oncol , vol.16 , pp. 1068-1077
    • Kudoh, S.1    Fujiwara, Y.2    Takada, Y.3
  • 24
    • 33646447066 scopus 로고    scopus 로고
    • Randomized Phase iii trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
    • Hanna N, Bunn PA, Langer C, et al. Randomized Phase iii trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-43
    • (2006) J Clin Oncol , vol.24 , pp. 2038-2043
    • Hanna, N.1    Bunn, P.A.2    Langer, C.3
  • 25
    • 66349102227 scopus 로고    scopus 로고
    • Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensivestage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124
    • Lara PN, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensivestage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:2530-5.
    • (2009) J Clin Oncol , vol.27 , pp. 2530-2535
    • Lara, P.N.1    Natale, R.2    Crowley, J.3
  • 26
    • 79959375226 scopus 로고    scopus 로고
    • Neuroendocrine tumors of the stomach: Chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma
    • Okita NT, Kato K, Takahari D, et al. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer 2011;14:161-5.
    • (2011) Gastric Cancer , vol.14 , pp. 161-165
    • Okita, N.T.1    Kato, K.2    Takahari, D.3
  • 27
    • 84865106659 scopus 로고    scopus 로고
    • Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas
    • Nakano K, Takahashi S, Yuasa T, et al. Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas. Jpn J Clin Oncol 2012;42:697-703.
    • (2012) Jpn J Clin Oncol , vol.42 , pp. 697-703
    • Nakano, K.1    Takahashi, S.2    Yuasa, T.3
  • 28
    • 84858659147 scopus 로고    scopus 로고
    • Multicenter retrospective analysis of systemic chemotherapy in poorly differentiated neuroendocrine carcinoma of the digestive system
    • Yamaguchi T, Machida N, Kasuga A, et al. Multicenter retrospective analysis of systemic chemotherapy in poorly differentiated neuroendocrine carcinoma of the digestive system. J Clin Oncol 2012;30:274.
    • (2012) J Clin Oncol , vol.30 , pp. 274
    • Yamaguchi, T.1    McHida, N.2    Kasuga, A.3
  • 29
    • 33847098794 scopus 로고    scopus 로고
    • Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing lowgrade and hogh-grade neuroendocrine tumors?
    • Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing lowgrade and hogh-grade neuroendocrine tumors? Cancer Chemother Pharmacol 2007;59: 637-42.
    • (2007) Cancer Chemother Pharmacol , vol.59 , pp. 637-642
    • Bajetta, E.1    Catena, L.2    Procopio, G.3
  • 30
    • 84884622485 scopus 로고    scopus 로고
    • Combination of capecitabine and oxaliplatin (CAPOX) is an effective option for the treatment of neuroendocrine tumors (NET). Poster presentation session
    • Stockholm, Sweden
    • Ferrarotto R, Testa L, Riechelmann RP, et al. Combination of capecitabine and oxaliplatin (CAPOX) is an effective option for the treatment of neuroendocrine tumors (NET). Poster presentation session. Meeting of the European Society of Medical Oncology, 2011, Stockholm, Sweden.
    • (2011) Meeting of the European Society of Medical Oncology
    • Ferrarotto, R.1    Testa, L.2    Riechelmann, R.P.3
  • 31
    • 33747061873 scopus 로고    scopus 로고
    • Phase II trial of paclitaxel, parboplatin and etoposide in advanced poorly differentiated neuroendocrine carcinoma: A Minnie Pearl Cancer Research Network Study
    • Hainsworth JD, Spigel DR, Litchy S, et al. Phase II trial of paclitaxel, parboplatin and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 2006;24:3548.
    • (2006) J Clin Oncol , vol.24 , pp. 3548
    • Hainsworth, J.D.1    Spigel, D.R.2    Litchy, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.